Bristol-Myers Squibb's Cobenfy launch shows strong initial sales and broad Medicaid/Medicare coverage, supporting its blockbuster potential in schizophrenia and future label expansions.

He also emphasized the U.S. approval and strong initial launch of Cobenfy, noted as the first novel mechanism for schizophrenia treatment in decades. Financial discipline remained a priority ...

Sales of Cobenfy, a new mind-stabilizing medicine, totaled $10 million in the final months of last year, results that fell in line with analyst expectations. Bristol Myers Squibb, which acquired ...

(Pediatric Research) Could the largest market for the new schizophrenia drug xanomeline and trospium chloride (Cobenfy) be in Alzheimer's disease psychosis, agitation, and cognition? Bristol Myers ...

The top 10 biopharma M&A deals of 2023 The company is counting heavily on Cobenfy, which was approved in September and was the crown jewel of the $14 billion buyout of Karuna. BMS reported sales ...

London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves ...

David Risinger’s rating is based on the impressive launch performance of Bristol-Myers Squibb’s Cobenfy, which is showing strong sales momentum since its introduction for schizophrenia treatment.

The first DLC pack for the fighting game has been revealed, and it's adding 11 new fighters to the mix. The Heroes of Justice Pack will be available to all season pass owners after it's released ...

We also achieved the landmark U.S. approval of Cobenfy last year for the treatment of schizophrenia in adults, and we expect this medicine to have a meaningful impact on patients and the company ...